Skip to main content
Figure 5 | Molecular Pain

Figure 5

From: The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy

Figure 5

Pharmacological blockade of CB 2 or CB 1 receptors does not alter cisplatin- or paclitaxel-induced neuropathic nociception. Neither the CB2 antagonist AM630 (3 mg/kg i.p.) nor the CB1 antagonist AM251 (3 mg/kg i.p.) altered cisplatin- (A, C) or paclitaxel- (B, D) evoked mechanical (A, B) and cold (C, D) allodynia. ### P < 0.001 vs. baseline (BL) prior to chemotherapy treatment, repeated measures ANOVA.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us